Rekah Pharmaceutical Industry Ltd.

Tel Aviv Stock Exchange REKA.TA

Rekah Pharmaceutical Industry Ltd. EBT Margin for the year ending December 31, 2023: -2.19%

Rekah Pharmaceutical Industry Ltd. EBT Margin is -2.19% for the year ending December 31, 2023, a -1,895.10% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Rekah Pharmaceutical Industry Ltd. EBT Margin for the year ending December 31, 2022 was 0.12%, a -95.82% change year over year.
Rekah Pharmaceutical Industry Ltd. EBT Margin for the year ending December 31, 2021 was 2.92%, a -45.22% change year over year.
Rekah Pharmaceutical Industry Ltd. EBT Margin for the year ending December 31, 2020 was 5.33%, a 130.64% change year over year.
Rekah Pharmaceutical Industry Ltd. EBT Margin for the year ending December 31, 2019 was 2.31%, a -51.55% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Tel Aviv Stock Exchange: REKA.TA

Rekah Pharmaceutical Industry Ltd.

CEO	Mr. Mordechai Elgrabli
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	30 Hamelach Street
Employees	427
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Key trends

Past 5 years